Search

With more than 20 years of experience, the Spanish company develops automation and digital solutions that enhance patient safety, optimize pharmaceutical processes, and improve the efficiency of

Embryotools, a biotechnology centre based at the Parc Científic de Barcelona (PCB), has achieved a new milestone in the field of assisted reproduction with the birth of the world’s first foal

Immunobiogram® is a test that measures in vitro the sensitivity (response) of each patient's immune system cells to immunosuppressive drugs, with the aim of facilitating the personalization of

We interviewed Pedro Martínez Córdoba, Councillor for Economic Promotion of Salamanca City Council, Gold Sponsor of BIOSPAIN 2025, to analyze the Abioinnova initiative.

Viva In Vitro, an AseBio member, has developed VIVA-ELISA, a biotechnology tool that rapidly detects activation of the NLRP3 inflammasome, enabling evaluation of the immune system’s ability to respond

Growing investment in R&D, eliminating unnecessary bureaucratic hurdles, and creating governance structures of its own are the main actions the European Union will undertake to reinforce its

We interviewed Román Rodríguez González, Regional Minister of Education, Science, Universities and Vocational Training of the Xunta de Galicia, Gold Sponsor, to analyze the Xunta’s commitment to

Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data

The host city for BIOSPAIN 2026 will be announced during the official events at BIOSPAIN 2025, while Barcelona is confirmed as the venue for the 2027 and 2029 editions.

Regenerative Agriculture aims to restore agricultural ecosystems through healthier soils, resilient crops, and systems that capture carbon, generate income, and address the challenges of climate

Eduard Viladesau, Managing Director of HIPRA Biotech Services, Gold Sponsor of BIOSPAIN 2025, analyzes the role of this business unit within HIPRA’s global strategy.

This is reflected in its 2024 Sustainability Report, which reviews the company's main ESG milestones

The investment combines funds from new investors like the EIC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and Takeda).

The study of the microbiota has gone from a focus limited to digestion to become a pillar of preventive and personalised medicine, opening up new therapeutic opportunities in multiple areas of health.